Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

NCT07266428 is registered in ClinicalTrials.gov with Ottimo Pharma Limited as lead sponsor.

NCT NCT07266428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Lead sponsor
Ottimo Pharma Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 17, 2025
Completion date
December 31, 2028
Enrollment
170 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors